- Home
- MITQ vs ADXN Comparison
MITQ vs ADXN Comparison
Compare MITQ & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | ADXN |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | 2 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 9.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MITQ | ADXN |
|---|---|---|
| Price | $0.64 | $7.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.7K | 8.0K |
| Earning Date | 11-14-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,477,000.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $6.51 |
| 52 Week High | $1.66 | $12.05 |
Technical Indicators
Market Signals| Indicator | MITQ | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 47.30 |
| Support Level | $0.65 | $7.01 |
| Resistance Level | $0.73 | $8.30 |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 4.21 | 41.41 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.